Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria

K. Na Bangchang, Timothy Davis, S. Looareesuwan, N.J. White, D. Bunnag, J. Karbwang

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmocokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg bodyweight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (V-d/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P <0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0.1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging.
    Original languageEnglish
    Pages (from-to)321-323
    JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
    Volume88
    DOIs
    Publication statusPublished - 1994

    Fingerprint

    Mefloquine
    Falciparum Malaria
    Pregnant Women
    Pharmacokinetics
    Chloroquine
    Acute malaria
    Therapeutics
    High Pressure Liquid Chromatography
    Pregnancy
    Pharmaceutical Preparations

    Cite this

    Na Bangchang, K. ; Davis, Timothy ; Looareesuwan, S. ; White, N.J. ; Bunnag, D. ; Karbwang, J. / Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994 ; Vol. 88. pp. 321-323.
    @article{704293c6b7a741c88108af4f45a4511b,
    title = "Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria",
    abstract = "Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmocokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg bodyweight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (V-d/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P <0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0.1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging.",
    author = "{Na Bangchang}, K. and Timothy Davis and S. Looareesuwan and N.J. White and D. Bunnag and J. Karbwang",
    year = "1994",
    doi = "10.1016/0035-9203(94)90101-5",
    language = "English",
    volume = "88",
    pages = "321--323",
    journal = "Transactions of the Royal Society of Tropical Medicine",
    issn = "0035-9203",
    publisher = "Elsevier",

    }

    Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. / Na Bangchang, K.; Davis, Timothy; Looareesuwan, S.; White, N.J.; Bunnag, D.; Karbwang, J.

    In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 88, 1994, p. 321-323.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria

    AU - Na Bangchang, K.

    AU - Davis, Timothy

    AU - Looareesuwan, S.

    AU - White, N.J.

    AU - Bunnag, D.

    AU - Karbwang, J.

    PY - 1994

    Y1 - 1994

    N2 - Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmocokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg bodyweight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (V-d/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P <0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0.1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging.

    AB - Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmocokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg bodyweight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (V-d/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P <0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0.1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging.

    U2 - 10.1016/0035-9203(94)90101-5

    DO - 10.1016/0035-9203(94)90101-5

    M3 - Article

    VL - 88

    SP - 321

    EP - 323

    JO - Transactions of the Royal Society of Tropical Medicine

    JF - Transactions of the Royal Society of Tropical Medicine

    SN - 0035-9203

    ER -